Table 3.

Circulating levels of total adiponectin and risk of multiple myeloma (MM) in stratified analyses^a

	Cases	Controls	Quartileb				Ptrend	Pintc
			Q1	Q2	Q3	Q4
By sex
Female	355	708	1.0 (ref)	0.85 (0.59-1.23)	0.66 (0.45-0.96)	0.66 (0.44-0.98)	0.029
Male	269	538	1.0 (ref)	1.08 (0.73-1.61)	0.85 (0.57-1.28)	0.59 (0.38-0.93)	0.011	0.526
By time to MM diagnosis
<6 years	282	562	1.0 (ref)	0.76 (0.51-1.14)	0.58 (0.38-0.89)	0.64 (0.42-0.99)	0.039
≥6 years	342	678	1.0 (ref)	1.13 (0.79-1.62)	0.88 (0.61-1.27)	0.62 (0.42-0.93)	0.008	0.215
By body mass index (BMI) at blood drawd
<25 kg/m2	212	463	1.0 (ref)	1.40 (0.82-2.38)	0.85 (0.50-1.43)	1.20 (0.73-2.00)	0.785
25-29.9 kg/m2	270	492	1.0 (ref)	0.76 (0.51-1.13)	0.70 (0.46-1.07)	0.41 (0.26-0.65)	<0.001
≥30 kg/m2	136	277	1.0 (ref)	0.93 (0.56-1.55)	0.73 (0.40-1.35)	0.41 (0.17-0.98)	0.039	0.041
By age at blood drawe
<65 years	314	623	1.0 (ref)	1.10 (0.77-1.58)	0.88 (0.60-1.29)	0.61 (0.39-0.95)	0.020
≥65 years	310	617	1.0 (ref)	0.80 (0.54-1.19)	0.61 (0.41-0.91)	0.61 (0.41-0.92)	0.017	0.400

^aBased on conditional logistic regression models unless otherwise noted.

^bQuartile cut points were defined based on the distribution of cohort- and sex-adjusted total adiponectin levels among controls, as follows: Q1, ≤8.64 μg/mL; Q2, 8.65-12.79 μg/mL; Q3, 12.80-17.79 μg/mL; Q4, ≥17.80 μg/mL.

^cTests of multiplicative interaction were based on the same models as those used for the stratified analyses and were performed using likelihood ratio tests comparing models with and without the interaction terms.

^dBased on unconditional logistic regression models adjusted for cohort, sex, age, race, and fasting status.

^eStrata were defined based on the age at blood draw for cases; matched sets were preserved.